Abstract

The use of natural compounds is promising in approaches to prevent and treat cancer. The long-term application of most currently employed chemotherapy techniques has toxic side effects. Eugenol, a phenolic phytochemical extracted from certain essential oils, has an anti-cancer effect. The modulation of autophagy can promote either the survival or apoptosis of cancer cells. Triple-negative (MDA-MB-231) and HER2 positive (SK-BR-3) breast cancer cell lines were treated with different doses of eugenol. Apoptosis was detected by a flow-cytometry technique, while autophagy was detected by acridine orange. Real-time PCR and Western blot assays were applied to investigate the effect of eugenol on the gene and protein expression levels of autophagy and apoptotic genes. Treating cells with different concentrations of eugenol significantly inhibited cell proliferation. The protein levels of AKT serine/threonine kinase 1 (AKT), forkhead box O3 (FOXO3a), cyclin dependent kinase inhibitor 1A (p21), cyclin-dependent kinase inhibitor (p27), and Caspase-3 and -9 increased significantly in Eugenol-treated cells. Eugenol also induced autophagy by upregulating the expression levels of microtubule-associated protein 1 light chain 3 (LC3) and downregulating the expression of nucleoporin 62 (NU p62). Eugenol is a promising natural anti-cancer agent against triple-negative and HER2-positive breast cancer. It appears to work by targeting the caspase pathway and by inducing autophagic cell death.

Highlights

  • Breast cancer has high morbidity and mortality rates among women worldwide [1]

  • The current data indicate that eugenol is a promising natural anti-cancer agent against triple-negative and HER2-positive breast cancer

  • It appears to work by targeting the caspase pathway and inducing autophagic cell death and by modulating the expression of several key proteins

Read more

Summary

Introduction

Breast cancer has high morbidity and mortality rates among women worldwide [1]. Triple-negative breast cancer (TNBC) is characterized by a lack of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor-2 (HER-2) expression [5,6]. This subtype represents approximately 15–20% of all BC with poor prognosis despite responding to conventional chemotherapy regimens [7]. HER2-positive breast cancer is associated with high HER2 expression and aggressive biological behavior [4]. The available treatment options for HER2-positive breast cancer range from certain cytotoxic agents such as doxorubicin to hormonal agents [11]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call